Issue 21, 2024, Issue in Progress
From the journal:

RSC Advances

Retraction: Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway

ZhongYu Jianga  and  Zhen Mao*b  

* Corresponding authors

a Department of Cancer Center, Zhejiang Quhua Hospital, Quzhou City, Zhejiang Province, China

b Department of Traditional Chinese Medicine, Gansu Provincial Hospital, No. 204, Donggang West Road, Chengguan District, Lanzhou City, Gansu Province, China
E-mail: maozhengssyy@163.com

Abstract

Retraction of ‘Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway’ by ZhongYu Jiang et al., RSC Adv., 2019, 9, 35473–35482, https://doi.org/10.1039/C9RA05933D.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/D4RA90047B
Article type
Retraction
Submitted
19 Apr 2024
Accepted
19 Apr 2024
First published
02 May 2024
This article is Open Access
Creative Commons BY license

RSC Adv., 2024,14, 14514-14514

Permissions

Request permissions

Retraction: Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway

Z. Jiang and Z. Mao, RSC Adv., 2024, 14, 14514 DOI: 10.1039/D4RA90047B

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements